跳至主要内容
临床试验/EUCTR2019-002545-38-DK
EUCTR2019-002545-38-DK进行中(未招募)1 期

Biodistribution of ablative fractional laser-assisted topical delivery of Vismodegib in basal cell carcinomas.

Bispebjerg Hospital, Department of Dermatology0 个研究点目标入组 34 人开始时间: 2019年6月24日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients above 18 years of age
  • Clinically and histologically verified nodular BCC with diameter =8 mm at baseline.
  • Signed informed consent.
  • Female subjects of childbearing potential1 must be confirmed not pregnant by a negative pregnancy test prior to study treatment and must use a safe contraceptive method for 24 months after study participation.
  • Patients with multiple BCC or locally advanced BCC in continuous oral vismodegib treatment (150 mg per day) for at least 14 days.
  • Male subjects with female partners of childbearing potential must use condom until 2 months after study participation.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 24

排除标准

  • Concomittant treatment with itraconazole, ketoconazole or imiquimod.
  • Concomittant chemotherapeutic treatment.
  • Infiltrative BCC or basosquamous carcinoma.
  • Pregnant or lactating women.
  • Allergies to vismodegib.
  • Patients with a tendency to form keloids.
  • Other skin diseases or tattoos in the treatment area.

研究者

发起方
Bispebjerg Hospital, Department of Dermatology

相似试验